January 17, 2012

Lights, Camera, Action!

Provectus' immunologic MOA announcement today is very important. I think immunology is growing from a valuation enhancer to a valuation driver.

The abstract, entitled Intralesional Injection of Melanoma with Rose Bengal Induces Regression of Untreated Synchronous Melanoma in a Murine Model, will be presented at the Society of Surgical Oncology Annual Meeting (March 21-24) in Orlando. The full abstract (i.e., the one paragraph that describes the work and outcome) is not yet publicly available, as far as I can tell.

Here's what comes to mind: the degree and proportion of such reversion of tumor-state that the authors' use of the word regression implies:
  • Complete regression? Partial regression? If so, a high degree or low degree? A combination of several states of regression?
  • What percentage of treated model tumors completed regressed? Regressed a lot? Partially regressed?
Recall from my Dinner at Eight post, we learned about "Moffitt’s excitement over their immunology work. They confirmed the bystander effect using a mouse lung metastasis model much harsher than the real disease. Moffitt's results were very robust and beyond what they have ever observed from other treatments using this model. PV-10 nearly cleared the lungs of all tumors..."

No comments:

Post a Comment